Phase II study of gemcitabine, cisplatin and sunitinib in patients with advanced urothelial carcinoma (UC).

被引：1
|
作者：
Galsky, M. B.
Sonpavde, G.
Hellerstedt, B. A.
McKenney, S. A.
Hutson, T. E.
Rauch, M. A.
Wang, Y.
Boehm, K. A.
Asmar, L.
机构：
[1] US Oncol Res, The Woodlands, TX USA
[2] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[3] Baylor Coll Med, Texas Oncol, Houston, TX 77030 USA
[4] Cent Austin Canc Ctr, Texas Oncol PA, Austin, TX USA
[5] Mamie McFadden Ward Canc Ctr, Texas Oncol PA, Beaumont, TX USA
[6] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4573
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4573
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC)
    Galsky, Matt D.
    Hellerstedt, Beth A.
    O'Rourke, Mark Allen
    Vogelzang, Nicholas J.
    Kocs, Darren M.
    McKenney, Scott A.
    Melnyk, Anton M.
    Hutson, Thomas E.
    Rauch, Mary Ann
    Wang, Yunfei
    Asmar, Lina
    Sonpavde, Guru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [2] Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC)
    Gallagher, D. J.
    Milowsky, M. I.
    Gerst, S. R.
    Iasonos, A.
    Riches, J.
    Boyle, M. G.
    Bajorin, D. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC)
    Gallagher, D. J.
    Milowsky, M. I.
    Gerst, S. R.
    Lasonos, A.
    Boyle, M.
    Riches, J.
    Bajorin, D. B.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 304 - 304
  • [4] Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC).
    Grivas, Petros
    Agarwal, Neeraj
    Siefker-Radtke, Arlene O.
    Daignault, Stephanie
    Puzanov, Igor
    MacVicar, Gary R.
    Levine, Ellis Glenn
    Srinivas, Sandy
    Twardowski, Przemyslaw
    Eisenberger, Mario A.
    Quinn, David I.
    Vaishampayan, Ulka N.
    Yu, Evan Y.
    Dawsey, Scott
    Day, Kathleen C.
    Day, Mark L.
    Smith, David C.
    Hussain, Maha
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.
    Pal, Sumanta K.
    Mortazavi, Amir
    Milowsky, Matthew I.
    Vaishampayan, Ulka N.
    Parikh, Mamta
    Lyou, Yung
    Wang, Peng
    Parikh, Rahul Atul
    Teply, Benjamin A.
    Dreicer, Robert
    Emamekhoo, Hamid
    Michaelson, M. Dror
    Hoimes, Christopher J.
    Zhang, Tian
    Srinivas, Sandy
    Kim, William Y.
    Liu, Glenn
    Frankel, Paul Henry
    Cui, Yuijie
    Lara, Primo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma
    Gitlitz, BJ
    Baker, C
    Chapman, Y
    Allen, HJ
    Bosserman, LD
    Patel, R
    Sanchez, JD
    Shapiro, RM
    Figlin, RA
    [J]. CANCER, 2003, 98 (09) : 1863 - 1869
  • [7] Final results of a phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC)
    Gallagher, D. J.
    Milowsky, M. I.
    Gerst, S. R.
    Iasonos, A.
    Boyle, M. G.
    Trout, A.
    Riches, J.
    Bajorin, D. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102.
    Philips, G.
    Sanford, B.
    Halabi, S.
    Bajorin, D.
    Small, E. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 236S - 236S
  • [9] Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma
    Philip, PA
    Zalupski, MM
    Vaitkevicius, VK
    Arlauskas, P
    Chaplen, R
    Heilbrun, LK
    Adsay, V
    Weaver, D
    Shields, AF
    [J]. CANCER, 2001, 92 (03) : 569 - 577
  • [10] Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC).
    Balar, A. V.
    Milowsky, M. I.
    Apolo, A. B.
    Ostrovnaya, I.
    Iasonos, A.
    Trout, A.
    Regazzi, A. M.
    Garcia-Grossman, I. R.
    Gallagher, D. J.
    Bajorin, D. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345